Data from the OrigAMI-4 trial support the accelerated approval of amivantamab and hyaluronidase-lpuj for this HNSCC population.
|Articles|July 1, 2008
Oncology NEWS International
- Oncology NEWS International Vol 17 No 7
- Volume 17
- Issue 7
RAS Mutations Enhance Chemotherapy in AML
Among 185 patients with acute myeloid leukemia, 34 had RAS mutations and 22 received high-dose cytarabine after complete remission.
Advertisement
Among 185 patients with acute myeloid leukemia, 34 had RAS mutations and 22 received high-dose cytarabine after complete remission. Their relapse rate was 45%, compared with 68% for high-dose patients with normal RAS, according to a CALGB study published online (JCO June 16, 2008). This could allow doctors to identify patients who would benefit from aggressive therapy.
Articles in this issue
over 18 years ago
National Cancer Survivors Dayover 18 years ago
New Indication for Velcade in Previously Untreated Myelomaover 18 years ago
Risk Factors for Mantle Cell Lymphoma Identifiedover 18 years ago
Antidiabetic Agent Metformin May Boost pCRs in Breast Caover 18 years ago
Eisai Seeks Full FDA Approval for Ontak for CTCLover 18 years ago
Symptom Screen Plus CA125 Detects Early Ovarian Caover 18 years ago
Cisplatin Linked to Cardiac Complications in Testicular Ca Patientsover 18 years ago
Updated X-ACT Study Results Presentedover 18 years ago
ThromboGenics and BioInvent Announce Alliance with Rocheover 18 years ago
Gene Signature Identifies Low-Risk Patients in MAGE-A3 TrialAdvertisement
Related to this article
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
The FDA assigned an April 9, 2027, target action date to resubmitted applications for rivoceranib plus camrelizumab in unresectable or metastatic hepatocellular carcinoma.
Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.
Data from the phase 3 MANGROVE study support the application for zanubrutinib/rituximab in this mantle cell lymphoma population.
Sunnie Kim, MD, discussed perioperative durvalumab plus FLOT, ctDNA-guided de-escalation, irAE monitoring, and biomarkers in gastroesophageal cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
Setting Up an HDR Brachytherapy Program Amid a National Decline
3
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
4
16-Fraction PMRT With IMN Irradiation Noninferior in High-Risk Breast Cancer
5